UnknownPhase 1

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias

Lead sponsor

Neurological Associates of West Los Angeles

Asset

Bosutinib

Listed sites

Recruiting sites

Enrollment

150

estimated

Study population

Mixed / unspecified dementia

Key I/E criterion

•Age 45-89

Primary endpoint

•Number of patients who are discontinued due to tolerability issues related

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID062016

NCT IDNCT02921477

Timeline

Milestones

Study start2016-09actual (month precision)

Study first posted2016-10-03estimated

Last update posted2022-09-28actual

Primary completion2023-12-31estimated

Study completion2025-12-31estimated

Assets

Drug assets

Bosutinib

Study populations

Who this study enrolls

Mixed / unspecified dementia

Eligibility

Who can enroll

Minimum age45 Years

Maximum age89 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Cognitive decline with mild cognitive impairment (Clinical Dementia Rating Stage 0.5) through moderate dementia (CDR Stages 1 and 2)

Exclusion criteria

•Subjects with a history of hypersensitivity to bosutinib

•Subjects with contraindications for lumbar puncture, such as bleeding abnormalities, use of anticoagulant medications, and local skin or spine abnormalities

•Reversible causes of cognitive impairment that explains the clinical status entirely, such as hypothyroidism, depression

•Advanced stages of any terminal illness or any active cancer that requires chemotherapy

•Pre-existing renal impairment

•Pre-existing hepatic impairment

•QT prolongation

•Significant cytopenia

•Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis

•Women who are pregnant, may become pregnant, or are breastfeeding

•Women of child-bearing potential and male participants with female partners who are of child-bearing potential

•Subjects unable to give informed consent or in vulnerable categories, such as prisoners

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Number of patients who are discontinued due to tolerability issues related to treatment

Time frame:1 year

event count, event

Publications (21)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.